Claims

What is claimed is:

1. A compound of Formula I:



I

wherein:

B is adenine, guanine, cytosine, uracil, thymine, 7-deazaadenine, 7-deazaguanine, 7-deaza-8-azaguanine, 7-deaza-8-azaadenine, inosine, nebularine, nitropyrrole, nitroindole, 2-aminopurine, 2-amino-6-chloropurine, 2,6-diaminopurine, hypoxanthine, pseudouridine, pseudocytosine, pseudoisocytosine, 5-propynylcytosine, isocytosine, isoguanine, 7-deazaguanine, 2-thiopyrimidine, 6-thioguanine, 4-thiothymine, 4-thiouracil, O^6-methylguanine, N^6-methyladenine, O^4-methylthymine, 5,6-dihydrothymine, 5,6-dihydrouracil, 4-methylindole, triazole, or pyrazolo[3,4-d]pyrimidine; and B is optionally substituted with one or more alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, hydroxy, or halo; and

R^1 is alkyl, alkenyl, alkynyl, cyano, azido, or fluoromethyl;

or a pharmaceutically acceptable salt or solvate thereof.

2. The compound of claim 1 wherein B is adenine, guanine, cytosine, uracil, or thymine; which B is optionally substituted with one or more alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, hydroxy, or halo.

3. The compound of claim 1 wherein B is 7-deazaadenine, 7-deazaguanine, 7-deaza-8-azaguanine, 7-deaza-8-azaadenine, inosine, nebularine, nitropyrrole, nitroindole, 2-aminopurine, 2-amino-6-chloropurine, 2,6-diaminopurine, hypoxanthine, pseudouridine, pseudocytosine, pseudoisocytosine, 5-

propynylcytosine, isocytosine, isoguanine, 7-deazaguanine, 2-thiopyrimidine, 6-thioguanine, 4-thiothymine, 4-thiouracil, O^6-methylguanine, N^6-methyladenine, O^4-methylthymine, 5,6-dihydrothymine, 5,6-dihydrouracil, 4-methylindole, triazole, or pyrazolo[3,4-d]pyrimidine; and B is optionally substituted with one or more alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, hydroxy, or halo

4. The compound of claim 1 wherein B is adenine, guanine, cytosine, uracil, or thymine.

5. The compound of claim 1 which is a compound of formula II:



II

wherein R^1 has any of the values defined in claim 1.

6. The compound of claim 1 which is a compound of formula III:



III

wherein R^1 has any of the values defined in claim 1.

7. The compound of any one of claims 1-6 wherein R^1 is alkyl.

8. The compound of any one of claims 1-6 wherein R^1 is methyl.

9. The compound of any one of claims 1-6 wherein R^1 is fluoromethyl.

10. The compound of any one of claims 1-6 wherein R^1 is alkenyl.

11. The compound of any one of claims 1-6 wherein R^1 is vinyl.

12. The compound of any one of claims 1-6 wherein R^1 is alkynyl.

13. The compound of any one of claims 1-6 wherein R^1 is ethynyl.

14. The compound of any one of claims 1-6 wherein R^1 is cyano.

15. The compound of any one of claims 1-6 wherein R^1 is azido.

16. A pharmaceutical composition, comprising an effective amount of a compound of Formula I as described in any one of claims 1-15, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient.

17. A pharmaceutical composition comprising an effective amount of a compound of Formula I as described in any one of claims 1-15, or a pharmaceutically acceptable salt or solvate thereof; a pharmaceutically acceptable excipient; and a therapeutically effective amount of another therapeutic agent.

18. The pharmaceutical composition of claim 16 which further comprises an AIDS treatment agent selected from an HIV inhibitor agent, an anti-infective agent, and an immunomodulator.

19. The pharmaceutical composition of claim 16 which further comprises an HIV-protease inhibitor.

20. The pharmaceutical composition of claim 16 which further comprises a reverse transcriptase inhibitor.

21. The pharmaceutical composition of claim 16 which further comprises a non-nucleoside reverse transcriptase inhibitor.

22. The pharmaceutical composition of claim 16 which further comprises an HIV integrase inhibitor.

23. A method of inhibiting a viral infection in an animal (e.g. a mammal), comprising administering to the animal, an effective amount of a compound of Formula I as described in any one of claims 1-15, or a pharmaceutically acceptable salt or solvate thereof.

24. A method for the treatment or prevention of the symptoms or effects of a viral infection in an animal comprising administering to the animal, an effective amount of a compound of Formula I as described in any one of claims 1-15, or a pharmaceutically acceptable salt or solvate thereof.

25. A method of inhibiting an HCV infection in an animal comprising administering to the animal, an effective amount of a compound of Formula I as described in any one of claims 1-15, or a pharmaceutically acceptable salt or solvate thereof.

26. A method for the treatment or prevention of the symptoms or effects of HCV infection in an infected animal comprising administering to the animal, an effective amount of a compound of Formula I as described in any one of claims 1-15, or a pharmaceutically acceptable salt or solvate thereof.

27. A method of inhibiting a viral enzyme comprising contacting a sample suspected of containing viral infected cells or tissues with an effective amount of a compound of Formula I as described in any one of claims 1-15, or a pharmaceutically acceptable salt or solvate thereof.

28. A method of inhibiting RNA-dependent RNA polymerase in an animal comprising administering to the animal, an effective amount of a compound of Formula I as described in any one of claims 1-15, or a pharmaceutically acceptable salt or solvate thereof.

29. A compound of Formula I as described in any one of claims 1-15, or a pharmaceutically acceptable salt or solvate thereof, for use in medical therapy.

30. The use of a compound of Formula I as described in any one of claims 1-15, or a pharmaceutically acceptable salt or solvate thereof, to prepare a medicament useful for inhibiting a viral infection in an animal.

31. The use of a compound of Formula I as described in any one of claims 1-15, or a pharmaceutically acceptable salt or solvate thereof, to prepare a medicament useful for the treatment or prevention of the symptoms or effects of a viral infection in an animal.

32. The use of a compound of Formula I as described in any one of claims 1-15, or a pharmaceutically acceptable salt or solvate thereof, to prepare a medicament useful for inhibiting an HCV infection in an animal.

33. The use of a compound of Formula I as described in any one of claims 1-15, or a pharmaceutically acceptable salt or solvate thereof, to prepare a medicament useful for the treatment or prevention of the symptoms or effects of HCV infection in an infected animal.

34. The use of a compound of Formula I as described in any one of claims 1-15, or a pharmaceutically acceptable salt or solvate thereof, to prepare a

medicament useful for inhibiting an RNA-dependent RNA polymerase in an animal.

35. A process for making a pharmaceutical composition comprising combining a compound of Formula I as described in any one of claims 1-15, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient.